2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
5 citations
,
January 2005 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New steroids were effective in blocking male hormone receptors in hamster prostates.
January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
Finding functions for unknown GPCRs is hard but key for making new drugs.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
1 citations
,
January 2020 Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
14 citations
,
April 2022 in “Molecules” Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
April 2026 in “International Journal of Clinical Oncology” The review by the Japanese Pharmacist-led Oncodermatology Study Team highlights that combining immune checkpoint inhibitors (ICIs) with chemotherapy or molecularly targeted therapy can exacerbate skin toxicities in Asian patients. Analyzing 28 studies out of 7,287 articles, the review focuses on capecitabine-induced hand-foot syndrome (HFS), multikinase inhibitor-induced hand-foot skin reaction (HFSR), taxane-induced alopecia, and EGFR inhibitor-related skin toxicities. The addition of ICIs was associated with a higher incidence of these skin toxicities, particularly capecitabine-related HFS and EGFR inhibitor-related skin issues. The findings emphasize the need for careful monitoring and management strategies to address these dermatologic side effects in combination therapies, as ICIs, while improving cancer survival rates, can amplify drug-specific skin toxicities through shared inflammatory pathways and immune cell recruitment to the skin. The study suggests that ICIs may enhance immune activity, potentially exacerbating skin toxicities, and highlights the need for preventive strategies and tailored treatment approaches for Asian populations.
4 citations
,
May 2022 in “Genes & Diseases”
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
54 citations
,
December 2004 in “PubMed” Cyclosporin A vesicles effectively regrow hair and reduce inflammation in alopecia areata.
1 citations
,
January 1989 Four antibodies were developed to help study hair follicle cell differentiation.
71 citations
,
February 1992 in “Journal of Cutaneous Pathology” Antibodies help identify glycoproteins in normal skin and tumor cells.
50 citations
,
December 2017 in “Nanoscale” Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
3 citations
,
January 2021 in “Minia Journal of Medical Research” Cyclophosphamide severely damages the intestinal lining in rats.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.